https://www.selleckchem.com/pr....oducts/pyrotinib.htm
3%-13.8%), 14.0% (13.0%-15.1%), and 13.3% (12.3%-14.4%) in 2003-06, 2007-10, 2011-14, and 2015-18, respectively (p[trend] = 0.24, N = 39569). This prevalence change was also minimal for most CKD stages. Non-Hispanic blacks and low-income people had a higher prevalence than all other races/ethnicities and income groups in most periods. Among risk factors, the prevalence of diabetes, high triglyceride, high total cholesterol, low HDL, obesity, abdominal obesity, and metabolic syndrome increased (p[trend] less then 0.05). The prevalence
Gefällt mir
Kommentar
Teilen
